Jason Pott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jason Pott has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Ben Bloom
Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London , London
4 shared publications Elinor C. Baker
Emergency Department, Royal London Hospital, Barts Health NHS Trust, Whitechapel Rd, London, E1 1BB, UK
3 shared publications- Yonathan Freund
Emergency Department, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France
3 shared publications - Daniel J. Pennington
Centre for Immunobiology and Infection, Blizard Institute, School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK
2 shared publications - Gerard Hernandez Mir
Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, E1 2AT, UK
2 shared publications - Imogen Skene
Barts Health NHS Trust, London, UK
2 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Wiley in Emergency Medicine International
- Vol. 2026 (1) , 3925923
Does Early Opioid Use for Relief of Acute Abdominal Pain Increase Use of Abdominal CT or Prolong Emergency Department Length of Stay?
Opioid use is common for emergency department (ED) patients presenting with undifferentiated abdominal pain (AbdPain). Whether the potential analgesic benefits of opioids are offset by prolonged ED length of stay (LOS)—possibly due to extended evaluations or increased diagnostic testing—remains unclear. The primary objective was to determine whether administration of an opioid, compared to a nonopioid drug, as initial analgesia in AbdPain patients is associated with longer ED LOS after adjusting for demographics and pain severity. Secondary objectives evaluated whether initial opioid use was associated with higher adjusted likelihood of ordering abdominal CT (CTabd) or white blood cell count (WBC) testing. This retrospective observational study analyzed 4 months of electronic health record data from a single UK health system, including consecutive adult ED patients presenting with AbdPain who received analgesia and had a documented pain score. Variables included demographic factors, initial pain level, and analgesic administered. ED workup variables included diagnostic testing (CTabd, WBC), LOS, and disposition. Categorical data were summarized as proportions with binomial exact 95% confidence intervals (CIs); continuous data were summarized with medians and interquartile ranges (IQRs). Univariable analyses used Wilcoxon rank‐sum or Pearson’s χ 2 tests. Multivariable analyses employed quantile median regression for LOS and logistic regression for secondary outcomes. During the study period, there were 884 patients meeting eligibility criteria. The median ED LOS was 7.7 h (IQR 5.0 to 11.9). CTabd and WBC were ordered in 362 (41.0%) and 797 (90.2%) of cases. Univariable analysis showed no association between initial opioid use and ED LOS (p = 0.255), CTabd ordering (p = 0.404), or WBC testing (p = 0.820). Multivariable modeling adjusting for operational factors, demographics, and pain score confirmed no significant association between initial opioid use and ED LOS (coefficient 0.18, 95% CI: −0.71–1.08, p = 0.684), CTabd (OR 1.12, 95% CI: 0.84–1.50, p = 0.430), or WBC testing (OR 0.91, 95% CI: 0.58–1.43, p = 0.698). Among ED patients with abdominal pain, initial opioid administration was not associated with longer LOS or increased use of diagnostic testing.
- 8 July 2026
- Published by Wiley in Emergency Medicine International
- Vol. 2026 (1) , 3925923
Open AccessDoes Early Opioid Use for Relief of Acute Abdominal Pain Increase Use of Abdominal CT or Prolong Emergency Department Length of Stay?
Opioid use is common for emergency department (ED) patients presenting with undifferentiated abdominal pain (AbdPain). Whether the potential analgesic benefits of opioids are offset by prolonged ED length of stay (LOS)—possibly due to extended evaluations or increased diagnostic testing—remains unclear. The primary objective was to determine whether administration of an opioid, compared to a nonopioid drug, as initial analgesia in AbdPain patients is associated with longer ED LOS after adjusting for demographics and pain severity. Secondary objectives evaluated whether initial opioid use was associated with higher adjusted likelihood of ordering abdominal CT (CTabd) or white blood cell count (WBC) testing. This retrospective observational study analyzed 4 months of electronic health record data from a single UK health system, including consecutive adult ED patients presenting with AbdPain who received analgesia and had a documented pain score. Variables included demographic factors, initial pain level, and analgesic administered. ED workup variables included diagnostic testing (CTabd, WBC), LOS, and disposition. Categorical data were summarized as proportions with binomial exact 95% confidence intervals (CIs); continuous data were summarized with medians and interquartile ranges (IQRs). Univariable analyses used Wilcoxon rank‐sum or Pearson’s χ 2 tests. Multivariable analyses employed quantile median regression for LOS and logistic regression for secondary outcomes. During the study period, there were 884 patients meeting eligibility criteria. The median ED LOS was 7.7 h (IQR 5.0 to 11.9). CTabd and WBC were ordered in 362 (41.0%) and 797 (90.2%) of cases. Univariable analysis showed no association between initial opioid use and ED LOS (p = 0.255), CTabd ordering (p = 0.404), or WBC testing (p = 0.820). Multivariable modeling adjusting for operational factors, demographics, and pain score confirmed no significant association between initial opioid use and ED LOS (coefficient 0.18, 95% CI: −0.71–1.08, p = 0.684), CTabd (OR 1.12, 95% CI: 0.84–1.50, p = 0.430), or WBC testing (OR 0.91, 95% CI: 0.58–1.43, p = 0.698). Among ED patients with abdominal pain, initial opioid administration was not associated with longer LOS or increased use of diagnostic testing.
- Open Access
Human-porcine transcriptomics reveals resuscitation-responsive pathways in trauma shock
Haemorrhage is the leading preventable cause of trauma death, primarily through ischaemic consequences that current treatments cannot adequately address. We combined human transcriptomic data (n=458) with a controlled porcine model of haemorrhagic shock to identify treatment-responsive molecular mechanisms. Using latent factorisation, we prioritised distinct molecular signatures of the human shock response, including stress signalling, neutrophil activation, and cytotoxic lymphocyte programmes. We assessed the behaviour of these pathways in the experimental porcine system, revealing that shock-initiated immune trajectories are not immutable: blood resuscitation normalised maladaptive transcriptomic changes whilst noradrenaline exacerbated them. While resuscitation modulated neutrophil, heat-shock, and barrier defence programmes, interferon and coagulation pathways were neither mortality-predictive nor treatment-responsive. A factor representing p38-MAPK/AP-1 stress signalling emerged as the dominant mortality-predictive pathway. An in silico small molecule screen identified p38 inhibitors as leading candidates for reversing shock-induced transcriptomic signatures. Our framework identifies modifiable pathways in trauma shock, prioritising p38-MAPK inhibition for therapeutic development and providing a systematic approach for trauma drug repurposing. One sentence summary : Human-porcine cross-analysis reveals treatment-modifiable molecular signatures of trauma shock, identifying potential therapeutic strategies.
Open AccessHuman-porcine transcriptomics reveals resuscitation-responsive pathways in trauma shock
Haemorrhage is the leading preventable cause of trauma death, primarily through ischaemic consequences that current treatments cannot adequately address. We combined human transcriptomic data (n=458) with a controlled porcine model of haemorrhagic shock to identify treatment-responsive molecular mechanisms. Using latent factorisation, we prioritised distinct molecular signatures of the human shock response, including stress signalling, neutrophil activation, and cytotoxic lymphocyte programmes. We assessed the behaviour of these pathways in the experimental porcine system, revealing that shock-initiated immune trajectories are not immutable: blood resuscitation normalised maladaptive transcriptomic changes whilst noradrenaline exacerbated them. While resuscitation modulated neutrophil, heat-shock, and barrier defence programmes, interferon and coagulation pathways were neither mortality-predictive nor treatment-responsive. A factor representing p38-MAPK/AP-1 stress signalling emerged as the dominant mortality-predictive pathway. An in silico small molecule screen identified p38 inhibitors as leading candidates for reversing shock-induced transcriptomic signatures. Our framework identifies modifiable pathways in trauma shock, prioritising p38-MAPK inhibition for therapeutic development and providing a systematic approach for trauma drug repurposing. One sentence summary : Human-porcine cross-analysis reveals treatment-modifiable molecular signatures of trauma shock, identifying potential therapeutic strategies.
- Open Access
The hyperacute plasma proteome reports injury severity and defines distinct trauma endotypes
The host response to traumatic injury is varied and unpredictable. Patients with subjectively similar injuries progress along divergent clinical paths, from uncomplicated recovery to extended hospitalisation, multiple organ dysfunction, and life-long ill health. The temporal certainty of trauma nonetheless provides immediate opportunity to predict clinical trajectory and intervene therapeutically. We demonstrate using machine-learning that the hyperacute plasma proteome can function as a physiology-driven indicator of injury severity. Moreover, it identifies two serious-injury endotypes that differentially predict unfavourable clinical trajectories. Notably, a prominent neuronal guidance protein signature, that reports vascular dysfunction and immune activation, together with an anti-coagulation/pro-fibrinolytic state, identify those patients who progress to adverse clinical outcomes. Together, these mechanistic insights into immediate host responses to serious trauma reveal tractable targets for future therapeutic interventions.
Open AccessThe hyperacute plasma proteome reports injury severity and defines distinct trauma endotypes
The host response to traumatic injury is varied and unpredictable. Patients with subjectively similar injuries progress along divergent clinical paths, from uncomplicated recovery to extended hospitalisation, multiple organ dysfunction, and life-long ill health. The temporal certainty of trauma nonetheless provides immediate opportunity to predict clinical trajectory and intervene therapeutically. We demonstrate using machine-learning that the hyperacute plasma proteome can function as a physiology-driven indicator of injury severity. Moreover, it identifies two serious-injury endotypes that differentially predict unfavourable clinical trajectories. Notably, a prominent neuronal guidance protein signature, that reports vascular dysfunction and immune activation, together with an anti-coagulation/pro-fibrinolytic state, identify those patients who progress to adverse clinical outcomes. Together, these mechanistic insights into immediate host responses to serious trauma reveal tractable targets for future therapeutic interventions.
- 11 September 2024
- Published by BMJ in Emergency Medicine Journal
- Vol. 42 (2) , 82-90
Sex and gender reporting in UK emergency medicine trials from 2010 to 2023: a systematic review
Background Female participants are underrepresented in randomised control trials conducted in urgent care settings. Although sex and gender are frequently reported within demographic data, it is less common for primary outcomes to be disaggregated by sex or gender. The aim of this review is to report sex and gender of participants in the primary papers published on research listed on the National Institute of Health and Care Research (NIHR) Trauma and Emergency Care (TEC) portfolio and how these data are presented. Methods This is a systematic review of the published outputs of interventional trials conducted in UK EDs. Interventional trials were eligible to be included in the review if they were registered on the NIHR TEC research portfolio from January 2010, if the primary paper was published before 31 December 2023 and if the research was delivered primarily in the ED. Trials were identified through the NIHR open data platform and the primary papers were identified through specific searches using MedLine, EMBASE and PubMed. The primary objective of the review is to quantify the proportion of sex-disaggregated or gender-disaggregated primary outcomes in clinical trials within UK emergency medicine. Results The initial search revealed 169 registered research projects on the NIHR TEC portfolio during the study period, of which 24 met the inclusion criteria. Overall, 76 719 participants were included, of which 31 374 (40%) were female. Only one trial (CRYOSTAT-2) reported a sex-disaggregated analysis of the effect of the intervention on either primary or secondary outcomes, and no sex-based difference in treatment effect was detected. Conclusions Fewer females than males were included in TEC trials from 2010 to 2023. One trial reported the primary outcome stratified by sex. There is significant scope to increase the scientific value of TEC trials to females by funders.
- 11 September 2024
- Published by BMJ in Emergency Medicine Journal
- Vol. 42 (2) , 82-90
Sex and gender reporting in UK emergency medicine trials from 2010 to 2023: a systematic review
Background Female participants are underrepresented in randomised control trials conducted in urgent care settings. Although sex and gender are frequently reported within demographic data, it is less common for primary outcomes to be disaggregated by sex or gender. The aim of this review is to report sex and gender of participants in the primary papers published on research listed on the National Institute of Health and Care Research (NIHR) Trauma and Emergency Care (TEC) portfolio and how these data are presented. Methods This is a systematic review of the published outputs of interventional trials conducted in UK EDs. Interventional trials were eligible to be included in the review if they were registered on the NIHR TEC research portfolio from January 2010, if the primary paper was published before 31 December 2023 and if the research was delivered primarily in the ED. Trials were identified through the NIHR open data platform and the primary papers were identified through specific searches using MedLine, EMBASE and PubMed. The primary objective of the review is to quantify the proportion of sex-disaggregated or gender-disaggregated primary outcomes in clinical trials within UK emergency medicine. Results The initial search revealed 169 registered research projects on the NIHR TEC portfolio during the study period, of which 24 met the inclusion criteria. Overall, 76 719 participants were included, of which 31 374 (40%) were female. Only one trial (CRYOSTAT-2) reported a sex-disaggregated analysis of the effect of the intervention on either primary or secondary outcomes, and no sex-based difference in treatment effect was detected. Conclusions Fewer females than males were included in TEC trials from 2010 to 2023. One trial reported the primary outcome stratified by sex. There is significant scope to increase the scientific value of TEC trials to females by funders.
- Open Access
- 14 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305276
Prospective observational study of peripheral intravenous cannula utilisation and frequency of intravenous fluid delivery in the emergency department—Convenience or necessity?
Background: Peripheral Intravenous Cannulas (PIVCs) are frequently utilised in the Emergency Department (ED) for delivery of medication and phlebotomy. They are associated with complications and have an associated cost to departmental resources. A growing body of international research suggests many of the PIVCs inserted in the ED are unnecessary. Methods: The objective of this study was to determine the rates of PIVC insertion and use. This was a prospective observational study conducted in one UK ED and one Italian ED. Adult ED patients with non-immediate triage categories were included over a period of three weeks in the UK ED in August 2016 and two weeks in the Italian ED in March and August 2017. Episodes of PIVC insertion and data on PIVC utilisation in adults were recorded. PIVC use was classified as necessary, unnecessary or unused. The proportion of unnecessary and unused PIVCs was calculated. PIVCs were defined as unnecessary if they were either used for phlebotomy only, or solely for IV fluids in patients that could have potentially been hydrated orally (determined against a priori defined criteria). PIVC classified as unused were not used for any purpose. Results: A total of 1,618 patients were included amongst which 977 PIVCs were inserted. Of the 977 PIVCs, 413 (42%) were necessary, 536 (55%) were unnecessary, and 28 (3%) were unused. Of the unnecessary PIVCs, 473 (48%) were used solely for phlebotomy and 63 (6%) were used for IV fluids in patients that could drink. Conclusions: More than half of PIVCs placed in the ED were unnecessary in this study. This suggests that clinical decision making about the benefits and risks of PIVC insertion is not being performed on an individual basis.
- 14 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305276
Open AccessProspective observational study of peripheral intravenous cannula utilisation and frequency of intravenous fluid delivery in the emergency department—Convenience or necessity?
Background: Peripheral Intravenous Cannulas (PIVCs) are frequently utilised in the Emergency Department (ED) for delivery of medication and phlebotomy. They are associated with complications and have an associated cost to departmental resources. A growing body of international research suggests many of the PIVCs inserted in the ED are unnecessary. Methods: The objective of this study was to determine the rates of PIVC insertion and use. This was a prospective observational study conducted in one UK ED and one Italian ED. Adult ED patients with non-immediate triage categories were included over a period of three weeks in the UK ED in August 2016 and two weeks in the Italian ED in March and August 2017. Episodes of PIVC insertion and data on PIVC utilisation in adults were recorded. PIVC use was classified as necessary, unnecessary or unused. The proportion of unnecessary and unused PIVCs was calculated. PIVCs were defined as unnecessary if they were either used for phlebotomy only, or solely for IV fluids in patients that could have potentially been hydrated orally (determined against a priori defined criteria). PIVC classified as unused were not used for any purpose. Results: A total of 1,618 patients were included amongst which 977 PIVCs were inserted. Of the 977 PIVCs, 413 (42%) were necessary, 536 (55%) were unnecessary, and 28 (3%) were unused. Of the unnecessary PIVCs, 473 (48%) were used solely for phlebotomy and 63 (6%) were used for IV fluids in patients that could drink. Conclusions: More than half of PIVCs placed in the ED were unnecessary in this study. This suggests that clinical decision making about the benefits and risks of PIVC insertion is not being performed on an individual basis.
- Open Access
- 1 April 2021
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 25 (26) , 1-76
Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT
Background: Tranexamic acid safely reduces mortality in traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain injury and can cause brain herniation and death. We assessed the effects of tranexamic acid in traumatic brain injury patients. Objective: To assess the effects of tranexamic acid on death, disability and vascular occlusive events in traumatic brain injury patients. We also assessed cost-effectiveness. Design: Randomised trial and economic evaluation. Patients were assigned by selecting a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients, caregivers and those assessing outcomes were masked to allocation. All analyses were by intention to treat. We assessed the cost-effectiveness of tranexamic acid versus no treatment from a UK NHS perspective using the trial results and a Markov model. Setting: 175 hospitals in 29 countries. Participants: Adults with traumatic brain injury within 3 hours of injury with a Glasgow Coma Scale score of ≤ 12 or any intracranial bleeding on computerised tomography scan, and no major extracranial bleeding, were eligible. Intervention: Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 1 g over 8 hours) or matching placebo. Main outcome measures: Head injury death in hospital within 28 days of injury in patients treated within 3 hours of injury. Secondary outcomes were early head injury deaths, all-cause and cause-specific mortality, disability, vascular occlusive events, seizures, complications and adverse events. Results: Among patients treated within 3 hours of injury (n = 9127), the risk of head injury death was 18.5% in the tranexamic acid group versus 19.8% in the placebo group (855/4613 vs. 892/4514; risk ratio 0.94, 95% confidence interval 0.86 to 1.02). In a prespecified analysis excluding patients with a Glasgow Coma Scale score of 3 or bilateral unreactive pupils at baseline, the results were 12.5% in the tranexamic acid group versus 14.0% in the placebo group (485/3880 vs. 525/3757; risk ratio 0.89, 95% confidence interval 0.80 to 1.00). There was a reduction in the risk of head injury death with tranexamic acid in those with mild to moderate head injury (166/2846 vs. 207/2769; risk ratio 0.78, 95% confidence interval 0.64 to 0.95), but in those with severe head injury (689/1739 vs. 685/1710; risk ratio 0.99, 95% confidence interval 0.91 to 1.07) there was no apparent reduction (p-value for heterogeneity = 0.030). Early treatment was more effective in mild and moderate head injury (p = 0.005), but there was no obvious impact of time to treatment in cases of severe head injury (p = 0.73). The risk of disability, vascular occlusive events and seizures was similar in both groups. Tranexamic acid is highly cost-effective for mild and moderate traumatic brain injury (base case of £4288 per quality-adjusted life-year gained). Conclusion: Early tranexamic acid treatment reduces head injury deaths. Treatment is cost-effective for patients with mild or moderate traumatic brain injury, or those with both pupils reactive. Future work: Further trials should examine early tranexamic acid treatment in mild head injury. Research on alternative routes of administration is needed. Limitations: Time to treatment may have been underestimated. Trial registration: Current Controlled Trials ISRCTN15088122, ClinicalTrials.gov NCT01402882, EudraCT 2011-003669-14, Pan African Clinical Trial Registry PACTR20121000441277. Funding: The project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 26. See the NIHR Journals Library website for further project information. In addition, funding was provided by JP Moulton Charitable Trust, Joint Global Health Trials (Medical Research Council, Department for International Development and the Wellcome Trust). This project was funded by the NIHR Global Health Trials programme.
- 1 April 2021
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 25 (26) , 1-76
Open AccessTranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT
Background: Tranexamic acid safely reduces mortality in traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain injury and can cause brain herniation and death. We assessed the effects of tranexamic acid in traumatic brain injury patients. Objective: To assess the effects of tranexamic acid on death, disability and vascular occlusive events in traumatic brain injury patients. We also assessed cost-effectiveness. Design: Randomised trial and economic evaluation. Patients were assigned by selecting a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients, caregivers and those assessing outcomes were masked to allocation. All analyses were by intention to treat. We assessed the cost-effectiveness of tranexamic acid versus no treatment from a UK NHS perspective using the trial results and a Markov model. Setting: 175 hospitals in 29 countries. Participants: Adults with traumatic brain injury within 3 hours of injury with a Glasgow Coma Scale score of ≤ 12 or any intracranial bleeding on computerised tomography scan, and no major extracranial bleeding, were eligible. Intervention: Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 1 g over 8 hours) or matching placebo. Main outcome measures: Head injury death in hospital within 28 days of injury in patients treated within 3 hours of injury. Secondary outcomes were early head injury deaths, all-cause and cause-specific mortality, disability, vascular occlusive events, seizures, complications and adverse events. Results: Among patients treated within 3 hours of injury (n = 9127), the risk of head injury death was 18.5% in the tranexamic acid group versus 19.8% in the placebo group (855/4613 vs. 892/4514; risk ratio 0.94, 95% confidence interval 0.86 to 1.02). In a prespecified analysis excluding patients with a Glasgow Coma Scale score of 3 or bilateral unreactive pupils at baseline, the results were 12.5% in the tranexamic acid group versus 14.0% in the placebo group (485/3880 vs. 525/3757; risk ratio 0.89, 95% confidence interval 0.80 to 1.00). There was a reduction in the risk of head injury death with tranexamic acid in those with mild to moderate head injury (166/2846 vs. 207/2769; risk ratio 0.78, 95% confidence interval 0.64 to 0.95), but in those with severe head injury (689/1739 vs. 685/1710; risk ratio 0.99, 95% confidence interval 0.91 to 1.07) there was no apparent reduction (p-value for heterogeneity = 0.030). Early treatment was more effective in mild and moderate head injury (p = 0.005), but there was no obvious impact of time to treatment in cases of severe head injury (p = 0.73). The risk of disability, vascular occlusive events and seizures was similar in both groups. Tranexamic acid is highly cost-effective for mild and moderate traumatic brain injury (base case of £4288 per quality-adjusted life-year gained). Conclusion: Early tranexamic acid treatment reduces head injury deaths. Treatment is cost-effective for patients with mild or moderate traumatic brain injury, or those with both pupils reactive. Future work: Further trials should examine early tranexamic acid treatment in mild head injury. Research on alternative routes of administration is needed. Limitations: Time to treatment may have been underestimated. Trial registration: Current Controlled Trials ISRCTN15088122, ClinicalTrials.gov NCT01402882, EudraCT 2011-003669-14, Pan African Clinical Trial Registry PACTR20121000441277. Funding: The project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 26. See the NIHR Journals Library website for further project information. In addition, funding was provided by JP Moulton Charitable Trust, Joint Global Health Trials (Medical Research Council, Department for International Development and the Wellcome Trust). This project was funded by the NIHR Global Health Trials programme.
- 1 November 2017
- Published by Elsevier in International Emergency Nursing
- Vol. 35, 1-6
Patients’ experience of trauma care in the emergency department of a major trauma centre in the UK
- 1 November 2017
- Published by Elsevier in International Emergency Nursing
- Vol. 35, 1-6
Patients’ experience of trauma care in the emergency department of a major trauma centre in the UK
- 3 February 2017
- Published by Taylor & Francis in Brain Injury
- Vol. 31 (3) , 304-311
Short-term neurocognitive and symptomatic outcomes following mild traumatic brain injury: A prospective multi-centre observational cohort study
Objective: To determine the short-term cognitive and symptomatic outcome following mild traumatic brain injury. Methods: Setting: Emergency Departments of two UK tertiary referral hospitals. Participants: Adult patients presenting to the Emergency Departments of the Royal London Hospital and Salford Royal Hospital with suspected traumatic brain injury within 24 hours and Glasgow Coma Score > 8. A non-TBI comparison group included adult patients with no head or neck injury. Design: Prospective multi-centre cohort study. Main measures: The Standardized Assessment of Concussion (SAC), the Concussion Symptom Inventory (CSI) and total number of symptoms, measured at baseline and 72 hours. Results: This study enrolled 189 patients with and 51 patients without TBI. Patients with TBI had marked cognitive impairment which persisted at 72 hours (SAC score at baseline = 25 [23–27] vs 72 hours = 25 [22–27]; p = 0.1). Patients with TBI had persistent high symptom severity, although this had decreased at 72 hours (CSI score at baseline = 9 [4–22] vs 72 hours = 5 [1–19], p = 0.002). A similar pattern was observed with the total number of symptoms (baseline = 4 [2–8] vs 72 hours = 0 [0–4]; p < 0.001). Patients with TBI had worse neurocognitive function, higher overall symptom severity and higher total number of symptoms compared with patients without TBI. Patients without TBI’ neurocognitive function and symptom severity remained constant, but the number of symptoms reduced between baseline and 72 hours. Conclusion: There is a cognitive deficit and symptom burden in patients with mild TBI presenting to the Emergency Department which persists at 72 hours.
- 3 February 2017
- Published by Taylor & Francis in Brain Injury
- Vol. 31 (3) , 304-311
Short-term neurocognitive and symptomatic outcomes following mild traumatic brain injury: A prospective multi-centre observational cohort study
Objective: To determine the short-term cognitive and symptomatic outcome following mild traumatic brain injury. Methods: Setting: Emergency Departments of two UK tertiary referral hospitals. Participants: Adult patients presenting to the Emergency Departments of the Royal London Hospital and Salford Royal Hospital with suspected traumatic brain injury within 24 hours and Glasgow Coma Score > 8. A non-TBI comparison group included adult patients with no head or neck injury. Design: Prospective multi-centre cohort study. Main measures: The Standardized Assessment of Concussion (SAC), the Concussion Symptom Inventory (CSI) and total number of symptoms, measured at baseline and 72 hours. Results: This study enrolled 189 patients with and 51 patients without TBI. Patients with TBI had marked cognitive impairment which persisted at 72 hours (SAC score at baseline = 25 [23–27] vs 72 hours = 25 [22–27]; p = 0.1). Patients with TBI had persistent high symptom severity, although this had decreased at 72 hours (CSI score at baseline = 9 [4–22] vs 72 hours = 5 [1–19], p = 0.002). A similar pattern was observed with the total number of symptoms (baseline = 4 [2–8] vs 72 hours = 0 [0–4]; p < 0.001). Patients with TBI had worse neurocognitive function, higher overall symptom severity and higher total number of symptoms compared with patients without TBI. Patients without TBI’ neurocognitive function and symptom severity remained constant, but the number of symptoms reduced between baseline and 72 hours. Conclusion: There is a cognitive deficit and symptom burden in patients with mild TBI presenting to the Emergency Department which persists at 72 hours.
- Open Access
- 2 September 2016
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 24 (1) , 1-8
The assessment of circulating volume using inferior vena cava collapse index and carotid Doppler velocity time integral in healthy volunteers: a pilot study
Assessment of circulating volume and the requirement for fluid replacement are fundamental to resuscitation but remain largely empirical. Passive leg raise (PLR) may determine fluid responders while avoiding potential fluid overload. We hypothesised that inferior vena cava collapse index (IVCCI) and carotid artery blood flow would change predictably in response to PLR, potentially providing a non-invasive tool to assess circulating volume and identifying fluid responsive patients. We conducted a prospective proof of concept pilot study on fasted healthy volunteers. One operator measured IVC diameter during quiet respiration and sniff, and carotid artery flow. Stroke volume (SV) was also measured using suprasternal Doppler. Our primary endpoint was change in IVCCI after PLR. We also studied changes in IVCCI after “sniff”, and correlation between carotid artery flow and SV. Passive leg raise was associated with significant reduction in the mean inferior vena cava collapsibility index from 0.24 to 0.17 (p < 0.01). Mean stroke volume increased from 56.0 to 69.2 mL (p < 0.01). There was no significant change in common carotid artery blood flow. Changes in physiology consequent upon passive leg raise normalised rapidly. Passive leg raise is associated with a decrease of IVCCI and increase in stroke volume. However, the wide range of values observed suggests that factors other than circulating volume predominate in determining the proportion of collapse with respiration. In contrast to other studies, we did not find that carotid blood flow increased with passive leg raise. Rapid normalisation of post-PLR physiology may account for this.
- 2 September 2016
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 24 (1) , 1-8
Open AccessThe assessment of circulating volume using inferior vena cava collapse index and carotid Doppler velocity time integral in healthy volunteers: a pilot study
Assessment of circulating volume and the requirement for fluid replacement are fundamental to resuscitation but remain largely empirical. Passive leg raise (PLR) may determine fluid responders while avoiding potential fluid overload. We hypothesised that inferior vena cava collapse index (IVCCI) and carotid artery blood flow would change predictably in response to PLR, potentially providing a non-invasive tool to assess circulating volume and identifying fluid responsive patients. We conducted a prospective proof of concept pilot study on fasted healthy volunteers. One operator measured IVC diameter during quiet respiration and sniff, and carotid artery flow. Stroke volume (SV) was also measured using suprasternal Doppler. Our primary endpoint was change in IVCCI after PLR. We also studied changes in IVCCI after “sniff”, and correlation between carotid artery flow and SV. Passive leg raise was associated with significant reduction in the mean inferior vena cava collapsibility index from 0.24 to 0.17 (p < 0.01). Mean stroke volume increased from 56.0 to 69.2 mL (p < 0.01). There was no significant change in common carotid artery blood flow. Changes in physiology consequent upon passive leg raise normalised rapidly. Passive leg raise is associated with a decrease of IVCCI and increase in stroke volume. However, the wide range of values observed suggests that factors other than circulating volume predominate in determining the proportion of collapse with respiration. In contrast to other studies, we did not find that carotid blood flow increased with passive leg raise. Rapid normalisation of post-PLR physiology may account for this.
- 1 December 2015
- Published by Wolters Kluwer Health in European Journal of Emergency Medicine
- Vol. 22 (6) , 407-412
Emergency department procedural sedation
The aim of this study was to develop a procedural sedation guideline and an audit tool to identify the medications chosen, the incidence of predefined adverse events and the factors associated with their occurrence. We performed a prospective observational study using a standardized proforma. We obtained data on patient demographics, the procedure performed, the drugs used and the dosages and predefined adverse events. Our target population was adult patients attending three urban UK teaching hospital Emergency Departments (EDs) over a 12-month period. We included all patients who were to undergo procedural sedation in the ED. Data were obtained on 414 patients. The majority of procedures were reductions of fractures and dislocations (89%). Midazolam was the sedative agent used most commonly (45%), and morphine was the most frequently used analgesic agent (36%). Overall 10% of sedations involved predefined complications (95% confidence interval: 7.1-12.9). There were no cases of airway obstruction requiring intervention; no patients showed clinical evidence of aspiration and no patient required intubation. Procedural success was 96%. Propofol was associated with fewer adverse events (95% confidence interval: 0.024-0.572), as well as higher procedural success. Procedural sedation and analgesia can be safely and effectively performed in the ED by appropriately trained emergency physicians.
- 1 December 2015
- Published by Wolters Kluwer Health in European Journal of Emergency Medicine
- Vol. 22 (6) , 407-412
Emergency department procedural sedation
The aim of this study was to develop a procedural sedation guideline and an audit tool to identify the medications chosen, the incidence of predefined adverse events and the factors associated with their occurrence. We performed a prospective observational study using a standardized proforma. We obtained data on patient demographics, the procedure performed, the drugs used and the dosages and predefined adverse events. Our target population was adult patients attending three urban UK teaching hospital Emergency Departments (EDs) over a 12-month period. We included all patients who were to undergo procedural sedation in the ED. Data were obtained on 414 patients. The majority of procedures were reductions of fractures and dislocations (89%). Midazolam was the sedative agent used most commonly (45%), and morphine was the most frequently used analgesic agent (36%). Overall 10% of sedations involved predefined complications (95% confidence interval: 7.1-12.9). There were no cases of airway obstruction requiring intervention; no patients showed clinical evidence of aspiration and no patient required intubation. Procedural success was 96%. Propofol was associated with fewer adverse events (95% confidence interval: 0.024-0.572), as well as higher procedural success. Procedural sedation and analgesia can be safely and effectively performed in the ED by appropriately trained emergency physicians.